ERBB2 and glioblastoma: Based on these results, we are currently performing the phase I, first-in-human clinical trial CAR2BRAIN (NCT03383978, clinicaltrials.gov) to explore an adoptive cellular immunotherapy with local application of NK-92/5.28.z cells in patients suffering from a relapse of a HER2-positive glioblastoma [22].